Izbiratel'naya modulyatsiya rosta pozitivnoy flory kishechnika - novaya kontseptsiya vozdeystviya metabolicheskogo prebiotika Khilak forte


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Intestinal dysbacteriosis is a disturbance of qualitative and/or quantitative composition of the normal flora. In the treatment of dysbiosis, probiotics (active agents of positive microflora) and prebiotics (oligosaccharides that promote the growth of positive flora) are widely used. The use of new class of probiotics, a metabolic prebiotics (eg, Hylak forte) is the most promising area in the treatment of dysbacteriosis. Metabolic prebiotics represent extracts of metabolites of positive flora which stimulate the growth of positive microbiota similar to oligosaccharide probiotics. The present article for the first time demonstrates the comparative metabolomics analysis of positive microflora underlying drug Hylak forte. Based on an analysis of possible molecular components, new mechanisms of therapeutic effect of this drug is formulated, promising synergistic effect in combination with Be, B2 vitamins, selenium, and glutathione. It was found that the positive flora produces and consumes metabolites associated with the processing of bile acids, biosynthesis and biotransformation of vitamins, selenium, prebiotic sugars, and short-chain fatty acids. Metabolomics analysis suggests that the metabolites in the Hylak forte promotes the survival of positive flora and can inhibit the growth of pathogenic intestinal microflora.

全文:

受限制的访问

参考

  1. Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 1974;27:961-79.
  2. Noack J, Kleessen B, Proll J, et al. Dietary guar gum and pectin stimulate intestinal microbial polyamine synthesis in rats. J Nutr 1998;128:1385-91.
  3. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. Altern Med Rev 2004; 9(2): 180-97.
  4. Куваева И.Б., Ладодо К.С. Микроэкологические и иммунные нарушения у детей. М., 1991.
  5. Отраслевой стандарт "Протокол ведения больных. Дисбактериоз кишечника" (ОСТ 91500.11.0004 от 09.06.2003, Приказ министерства здравоохранения РФ № 231 от 09.06.2003).
  6. Kilkkinen A, Pietinen P, Klaukka T, et al. Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 2002; 155:472-77.
  7. Hurley BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 2002; 162:2177-84.
  8. Macfarlane GT, Gibson GR. Metabolic activities of the normal colonic flora. In: Gibson SAW, ed. Human Health: The Contribution of Microorganisms. London: Springer- Verlag, 1994; 17-53.
  9. Macfarlane S, Macfarlane GT. Proteolysis and amino acid fermentation. In: Gibson GR, Macfarlane GT, eds. Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology. Boca Raton, FL: CRC Press, 1995;75-100.
  10. Kruis W, Forstmaier G, Scheurlen C, Stellaard F. Effect of diets low and high in refined sugars on gut transit, bile acid metabolism, and bacterial fermentation. Gut 1991;32:367-71.
  11. WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (October 2001). "Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria". Food and Agriculture Organization of the United Nations, World Health Organization. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf.
  12. Лиманова О.А., Федотова Л.Э., Садин А.В. Клиническая фармакология препаратов, применяемых для лечения дисбактериоза кишечника. Иваново, 2007. 23 с.
  13. Roberfroid M. Prebiotics: the concept revisited. J Nutr 2007;137(3):830-37.
  14. Таболин В.А., Бельмер С.В., Гасилина Т.В. и др. Рациональная терапия дисбактериоза кишечника у детей. Методические рекомендации. М., 1998.
  15. Biville F, Laurent-Winter C, Danchin A. In vivo positive effects of exogenous pyrophosphate on Escherichia coli cell growth and stationary phase survival. Res Microbiol 1996;147(8):597-608.
  16. Gritsenko VA, Brudastov IuA, Kudria EV, Vasil'eva LI. Comparative analysis of the sensitivity of entero-bacteria to bile. Zh Mikrobiol Epidemiol Immunobiol 2002;(3):65-7.
  17. Kyriakidis DA, Tiligada E. Signal transduction and adaptive regulation through bacterial two-component systems: the Escherichia coli AtoSC paradigm. Amino Acids 2009;37(3):443.
  18. Hori Y, Nihei Y, Kurokawa Y, Kuramasu A, et al. Accelerated clearance of Escherichia coli in experimental peritonitis of histamine-deficient mice. J Immunol 2002;169(4):1978-83.
  19. Bailey MT, Coe CL. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev Psychobiol 1999; 35:146-55.
  20. Lyte M, Ernst S. Catecholamine induced growth of gram negative bacteria. Life Sci 1992;50:203-12.
  21. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2004;2(2): 95-108.
  22. Bukharin OV, Petrunova NB. Microbial “friend-foe'' identification in human intestine microsym-biocenosis. Zh Mikrobiol Epidemiol Immunobiol 2011;(6):46-51.
  23. Yates EA, Philipp B, Buckley C, et al. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect Immun 2002;70(10):5635-46.
  24. Wang XD, de Boer PA, Rothfield LI. A factor that positively regulates cell division by activating transcription of the major cluster of essential cell division genes of Escherichia coli. EMBO J 1991;10(11):3363- 72.
  25. Qazi S, Middleton B, Muharram SH, et al. N-acylhomoserine lactones antagonize virulence gene expression and quorum sensing in Staphylococcus aureus. Infect Immun 2006;74(2):910-19.
  26. Hall RA, Turner KJ, Chaloupka J, et al. The quorum-sensing molecules farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans. Eukaryot Cell 2011;10(8):1034-42.
  27. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol 2001;55:165-99.
  28. Diggle SP, Gardner A, West SA, Griffin AS. Evolutionary theory of bacterial quorum sensing: when is a signal not a signal? Philos Trans R Soc Lond B Biol Sci 2007;362(1483):1241-49.
  29. Lyte M, Frank CD, Green BT. Production of an autoinducer of growth by norepinephrine cultured Escherichia coli 0157:H7. FEMS Microbiol Lett 1996;139:155-59.
  30. Shimazaki J, Furukawa S, Ogihara H, Morinaga Y. L-Tryptophan prevents Escherichia coli biofilm formation and triggers biofilm degradation. Biochem Biophys Res Commun 2 012;419(4): 715-18.
  31. Vacheva A, Ivanova R, Paunova-Krasteva T, Stoitsova S. Released products of pathogenic bacteria stimulate biofilm formation by Escherichia coli K-12 strains. Antonie Van Leeuwenhoek 2012;102(1):105-19.
  32. Kumari A, Pasini P, Deo SK, et al. Biosensing systems for the detection of bacterial quorum signaling molecules. Anal Chem 2006;78(22): 7603-609.
  33. Vakhitov TIa, Protasov EA, Visnol'd NV, et al. isolation and identification of growth stimulators of Escherichia coli M-17. Zh Mikrobiol Epidemiol immunobiol 2003;(2):7-12.
  34. Kanehisa M, Goto S, Hattori M, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34:D354-57.
  35. Caspi R, Foerster H, Fulcher CA, et al. MetaCyc: a multiorganism database of metabolic pathways and enzymes. Nucleic Acids Res 2006; 34:D511-16.
  36. Joshi-Tope G, Gillespie M, Vastrik i, et al. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 2005;33 :D428-32.
  37. Торшин И.Ю., Громова О.А. 25 мгновений молекулярной фармакологии. М., 2012. 694 с.
  38. Bentley R, Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol Rev 1982;46(3):241-80.
  39. Reid G, Howard J, Gan BS. Can bacterial interference prevent infection? Trends Microbiol 2001;9(9):424-28.
  40. Aihara K, Kajimoto O, Hirata H, Takahashi R, Nakamura Y. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with highnormal blood pressure or mild hypertension. J Am Coll Nutr 2005;24(4):257-65.
  41. Schlegel A, Bohm A, Lee SJ, et al. Network regulation of the Escherichia coli maltose system. J Mol Microbiol Biotechnol2002;4(3):301 -07.
  42. Bochner BR, Gadzinski P, Panomitros E. Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. Genome Res 2001;11(7):1246-55.
  43. Регистр Лекарственных Средств, Москва, 2012, 1672 с.
  44. Florkiewicz H, Szurska G. [role of the hylak forte preparation in the prevention of dysbacteriosis following intraoral antibiotic therapy]. Pol Tyg Lek 1963;18:1066-68.
  45. Копанев Ю.А. Применение хилак форте для коррекции микроэкологических нарушений и функциональных расстройств у детей и взрослых// Трудный пациент 2007. Т. 5. № 10. С. 46-52.
  46. Плоскирева А.А., Усенко Д.В., Горелов А.В. Адаптогенные свойства метаболитного пребиотика Хилак Форте // Инфекционные болезни. 2010. Т. 8. № 1. С. 48-54.
  47. Агафонова Н.А., Яковенко Э.П., Иванов А.Н. и др. Особенности терапии больных с постинфекционным синдромом раздраженного кишечника // Фарматека 2011. № 15. С. 50-5.
  48. Бурков С.Г., Макух Е.А. Синдром раздраженного кишечника в поликлинической практике // Фарматека 2009. № 8. С. 60-4.
  49. Ардатская М.Д. Пре- и пробиотики в коррекции микроэкологических нарушений кишечника // Фарматека 2011. № 12. С. 62-8.
  50. Грачева Н.М., Малышев Н.А., Леонтьева Н.И. и др. Восстановление метаболитного статуса кишечной микрофлоры у больных хроническими заболеваниями желудочнокишечного тракта // Инфекционные болезни 2006. Т. 4. № 2. С. 37-41.
  51. Rudkowski Z, Bromirska J. Reduction of the duration of salmonella excretion in infants with Hylak forte. Padiatr Padol 1991 ;26(2):111-14.
  52. Грачева Н.М., Партин О.С., Леонтьева Н.И. и др. Применение современного пребиотика хилак форте в комплексной терапии больных острыми кишечными инфекциями и хроническими заболеваниями желудочно-кишечного тракта с явлениями дисбактериоза кишечника // Эпидемиология и инфекционные болезни 2003. № 5. 32 с.
  53. Zboril V, Prokopova L, Geislerova V, et al. The effect of Hylak drops on symptomatology in persons with irritable bowel syndrome.Vnitr Lek 1992;38(8):764-68.
  54. Аляви А.Л., Ходжиматова Ж.А. Оценка эффективности озонотерапии и препарата Хилак-форте при комплексном лечении синдрома раздраженного кишечника // Физиотерапия, бальнеология и реабилитация 2009. № 1. С. 29-32.
  55. Чернусь Н.П. Особенности микробиоценоза толстой кишки у пациентов с функциональными запорами и его коррекция пробиотиком Хилак форте // Клиницист 2006. № 3. С. 47-53.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2012
##common.cookie##